AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Bad news for Novo Nordisk weight-loss drug Wegovy
July 04, 2024 10:57 PM AEST| By InvezzNovo Nordisk A/S (CPH: NOVO-B) is in the green today even though a Harvard study said its weight loss drug may increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION). The rare eye disease can ultimately result in loss of v...
How much could the Alzheimer’s drug add to Eli Lilly’s revenue?
July 04, 2024 05:11 AM AEST| By InvezzThe new Alzheimer’s drug is unlikely to benefit shares of Eli Lilly & Co (NYSE: LLY) as quickly as its weight-loss drug, says Evan Seigerman. He’s a senior research analyst at BMO Capital Markets. LLY is globally one of the most valuable pharmace...
Eli Lilly receives FDA approval for its Alzheimer’s drug Kisunla
July 03, 2024 04:59 AM AEST| By InvezzEli Lilly & Co (NYSE: LLY) received approval for its Alzheimer’s drug from the Food & Drug Administration on Tuesday. The development is significant as it expands treatment options for the neurological disorder that affects close to 7 m...
CVS Health stock price analysis as Walgreens implodes
June 28, 2024 11:02 AM AEST| By InvezzCVS Health (NYSE: CVS) stock price is imploding as concerns about the pharmacy business continue. It has already plunged by more than 43% from its 2022 highs and is hovering at its lowest point since November 2020. Pharmacy woes are continuing The ph...
GSK’s (LSE/NYSE: GSK) Omjjara Approved in Japan for Myelofibrosis Treatment
June 27, 2024 07:24 PM AEST| By Team Kalkine MediaGSK plc (LSE/,NYSE: GSK,) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is a once-daily, oral inhibitor of JAK1/JAK2 and activin A receptor type...
Zealand Pharma stock rallies 20%: what happened?
June 21, 2024 11:55 PM AEST| By InvezzZealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-time high. Why is it significant for Zeal...
Why has the Sarepta stock price (SRPT) gone up more than 35%?
June 21, 2024 07:12 PM AEST| By InvezzSarepta Therapeutics (NASDAQ: SRPT), a pharmaceutical company that describes itself as specializing in “precision genetic medicine for rare diseases”, saw its stock price shoot up by 36% in after-hours trading last night. But why? Ground-breaking med...
Evotec (NASDAQ: EVO) and Bristol Myers Squibb: Advancing Neuroscience Innovation
June 12, 2024 06:12 PM AEST| By Team Kalkine MediaEvotec SE (,NASDAQ: EVO,) has announced a significant leap forward in its neuroscience collaboration with Bristol Myers Squibb (,NYSE: BMY,), marking a milestone achievement in the quest for novel treatments for neurodegenerative diseases. The latest...
Belite Bio's (NASDAQ: BLTE) Tinlarebant Granted Sakigake Designation for STGD1 Treatment
June 12, 2024 06:06 PM AEST| By Team Kalkine MediaBelite Bio, Inc (,NASDAQ: BLTE,), a distinguished player in the realm of clinical-stage biopharmaceutical drug development, has achieved a significant milestone with its lead pipeline candidate, Tinlarebant. The company proudly announces that Tinlare...
Alvotech (NASDAQ: ALVO) and STADA Forge Strategic Alliance to Expand Access to Biosimilars
June 11, 2024 06:29 PM AEST| By Team Kalkine MediaAlvotech (,NASDAQ: ALVO,) and STADA, two prominent players in the pharmaceutical industry, have announced the extension of their strategic alliance, aiming to bolster access to high-quality and cost-effective biosimilars. The latest development sees...
111, Inc. (NASDAQ: YI) and Scrianen Forge Strategic Partnership to Revolutionize Healthcare Distribution in China
June 11, 2024 06:24 PM AEST| By Team Kalkine MediaIn a significant move set to reshape the landscape of healthcare distribution in China, 111, Inc. (,NASDAQ: YI,) and Beijing Scrianen Pharmaceutical Co., Ltd. (Scrianen) have joined forces in a strategic direct supply partnership. The announcement, m...
Alzheimer’s could be a ‘very big category’ for Eli Lilly: former FDA commissioner
June 11, 2024 10:17 AM AEST| By InvezzAlzheimer’s could eventually be a “very big category” for Eli Lilly & Co (NYSE: LLY), says Dr Scott Gottlieb. He’s the former commission of the U.S. Food & Drug Administration. FDA advisors vote in favour of Lilly’s donanemab Lilly received b...
Very good news for Geron stock price: now what?
June 07, 2024 09:49 PM AEST| By InvezzGeron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest actions by the Food and Drug Administration (FDA). After closing at $3.90 on Thursday, the stock surged by more than 20% to over $4.66, as we predict...
Canopy Growth just proposed stock sale: find out more
June 06, 2024 11:26 PM AEST| By InvezzCanopy Growth Corp (NASDAQ: CGC) says it has established an “at-the-market equity program”. Shares of the cannabis firm are in the red at writing. Canopy Growth may sell up to $250 million of it stock The program will enable $CGC to raise up to $250...
Insmed stock doubles on positive ASPEN study results
May 28, 2024 09:08 PM AEST| By InvezzShares of Insmed Inc (NASDAQ: INSM) more than doubled on Tuesday after the biopharmaceutical firm reported positive results for its ASPEN study. Insmed stock soars on topline results from ASPEN study The Phase 3 trial evaluated “efficacy, safety, and...
Verastem opened 70% down on Friday: what happened?
May 25, 2024 01:30 AM AEST| By InvezzVerastem Inc (NASDAQ: VSTM) opened nearly 70% down this morning even though the pharmaceutical firm reported positive interim data for its combination therapy as a treatment of pancreatic cancer. Here’s what is hitting $VSTM today The oncology...
Medtronic (NYSE: MDT) Reports Strong Q4 and FY24 Financial Results, Issues FY25 Guidance
May 24, 2024 08:19 AM AEST| By Team Kalkine MediaMedtronic plc (,NYSE: MDT,) today released its financial results for the fourth quarter (Q4) and fiscal year 2024 (FY24), which ended on April 26, 2024. The company reported steady growth, increased shareholder returns, and provided guidance for FY25...
Regeneron's (NASDAQ: REGN) Q1 financial performance fell short to meet EPS and revenue forecasts
May 03, 2024 04:03 PM AEST| By Team Kalkine MediaHighlights,Regeneron’s Q1 earnings fell short of projections, with lower-than-expected EPS and revenue.,The company’s overall revenues dipped by 1% to US$3.15 billion compared to the same period in 2023.,In April 2024, Regeneron made strategic moves...
UnitedHealth Group (NYSE: UNH) Reports Strong First Quarter 2024 Performance Amid Cyberattack Challenges
April 17, 2024 03:56 PM AEST| By Team Kalkine MediaUnitedHealth Group (,NYSE: UNH,), a prominent player in the healthcare and well-being sector, disclosed its first quarter 2024 earnings report on April 16, 2024. The company, listed on the New York Stock Exchange under the ticker symbol UNH, operates...
Roche's Breakthrough Blood Test for Alzheimer's Receives FDA Designation
April 12, 2024 07:27 AM AEST| By Team Kalkine MediaRoche (SIX: RO, ROG; OTCQX:,RHHBY,), with over 20 years of dedicated scientific research in Alzheimer's disease, is committed to advancing detection methods and treatments to combat this debilitating condition. With a vision of early detection and ha...
